Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer entities : Novocure limited save search
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
Published: 2024-04-05 (Crawled : 12:30) - biospace.com/
NVCR | $12.055 1.9% 1.87% 750K
|
Health Technology
|
| O: -4.16%
H: 1.07%
C: -2.28%
association cancer pancreatic tumor research preclinical for meeting
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
Published: 2024-01-18 (Crawled : 12:30) - biospace.com/
NVCR | $12.055 1.9% 1.87% 750K
|
Health Technology
|
| O: 4.19%
H: 21.15%
C: 12.06%
fda lung cancer cell application therapy
Novocure Provides Update on Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy in Platinum-resistant Ovarian Cancer
Published: 2023-08-28 (Crawled : 14:30) - biospace.com/
NVCR | $12.055 1.9% 1.87% 750K
|
Health Technology
|
| O: -33.69%
H: 6.18%
C: -5.75%
gog-3029 update cancer tumor trial therapy
Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer
Published: 2023-07-21 (Crawled : 13:20) - biospace.com/
NVCR | $12.055 1.9% 1.87% 750K
|
Health Technology
|
| O: -0.75%
H: 2.79%
C: 1.59%
favorable cancer pancreatic tumor trial therapy
LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Published: 2023-06-06 (Crawled : 15:00) - biospace.com/
NVCR | $12.055 1.9% 1.87% 750K
|
Health Technology
|
| O: -9.53%
H: 0.68%
C: -37.04%
lung cancer cell extension trial
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Published: 2023-06-06 (Crawled : 12:00) - globenewswire.com
ZLAB | $15.13 0.93% 0.93% 470K
|
Health Technology
|
| O: -2.43%
H: 0.67%
C: -2.98%
NVCR | $12.055 1.9% 1.87% 750K
|
Health Technology
|
| O: -9.53%
H: 0.68%
C: -37.04%
lung cancer cell extension trial
Novocure Pledges $3 Million to Conquer Cancer®, the ASCO Foundation, to Support Cancer Research and Education
Published: 2023-06-01 (Crawled : 13:00) - biospace.com/
NVCR | $12.055 1.9% 1.87% 750K
|
Health Technology
|
| O: 0.68%
H: 5.27%
C: 3.6%
cancer asco research education
Novocure Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2023-04-26 (Crawled : 15:00) - biospace.com/
NVCR | $12.055 1.9% 1.87% 750K
|
Health Technology
|
| O: 0.26%
H: 7.67%
C: 4.81%
lung presentation cancer cell meeting trial results
Zai Lab Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2023-04-26 (Crawled : 15:00) - globenewswire.com
ZLAB | $15.13 0.93% 0.93% 470K
|
Health Technology
|
| O: 2.65%
H: 1.91%
C: -2.78%
NVCR | $12.055 1.9% 1.87% 750K
|
Health Technology
|
| O: 0.26%
H: 7.67%
C: 4.81%
lung presentation cancer cell meeting trial results
Novocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer
Published: 2023-03-01 (Crawled : 14:00) - biospace.com/
NVCR | $12.055 1.9% 1.87% 750K
|
Health Technology
|
| O: 0.69%
H: 0.7%
C: -1.57%
tumor lung cancer study brain metastases
Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer
Published: 2023-02-15 (Crawled : 15:20) - biospace.com/
NVCR | $12.055 1.9% 1.87% 750K
|
Health Technology
|
| O: -0.37%
H: 2.98%
C: 2.18%
tumor cancer study pancreatic
Novocure Announces Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
Published: 2023-01-05 (Crawled : 13:00) - biospace.com/
NVCR | $12.055 1.9% 1.87% 750K
|
Health Technology
|
| O: 53.35%
H: 10.97%
C: 9.85%
lung cancer study
Zai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
Published: 2023-01-05 (Crawled : 13:00) - globenewswire.com
ZLAB | $15.13 0.93% 0.93% 470K
|
Health Technology
|
| O: 33.43%
H: 10.05%
C: 6.27%
NVCR | $12.055 1.9% 1.87% 750K
|
Health Technology
|
| O: 53.35%
H: 10.97%
C: 9.85%
lung cancer study
Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer
Published: 2022-06-21 (Crawled : 13:20) - biospace.com/
NVCR | $12.055 1.9% 1.87% 750K
|
Health Technology
|
| O: 1.86%
H: 0.0%
C: 0.0%
keytruda cancer
Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer
Published: 2022-06-03 (Crawled : 13:00) - biospace.com/
NVCR | $12.055 1.9% 1.87% 750K
|
Health Technology
|
| O: 5.37%
H: 2.15%
C: -4.71%
ef-31 treatment cancer
Novocure Announces 19 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2022 Suggesting Broad Applicability of Tumor Treating Fields
Published: 2022-04-08 (Crawled : 12:00) - biospace.com/
NVCR | $12.055 1.9% 1.87% 750K
|
Health Technology
|
| O: -0.7%
H: 2.08%
C: 0.73%
research cancer
Novocure Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 Study of Tumor Treating Fields in Ovarian Cancer
Published: 2022-03-23 (Crawled : 12:00) - novocure.com
NVCR | $12.055 1.9% 1.87% 750K
|
Health Technology
|
| O: -2.16%
H: 2.52%
C: -0.91%
cancer phase 3 ovarian cancer
Novocure Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-small Cell Lung Cancer
Published: 2021-11-22 (Crawled : 12:30) - novocure.com
NVCR | $12.055 1.9% 1.87% 750K
|
Health Technology
|
| O: -4.3%
H: 0.0%
C: 0.0%
lung cancer cancer phase 3 trial enroll
Novocure Announces Last Patient Enrolled in Phase 3 Pivotal INNOVATE-3 Trial of Tumor Treating Fields in Ovarian Cancer
Published: 2021-10-28 (Crawled : 12:00) - biospace.com/
NVCR | $12.055 1.9% 1.87% 750K
|
Health Technology
|
| O: -4.1%
H: 0.0%
C: -4.24%
cancer phase 3 ovarian cancer trial enroll
Zai Lab and Novocure Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China
Published: 2021-10-04 (Crawled : 12:00) - globenewswire.com
ZLAB | $15.13 0.93% 0.93% 470K
|
Health Technology
|
| O: -4.58%
H: 2.65%
C: 0.49%
NVCR | $12.055 1.9% 1.87% 750K
|
Health Technology
|
| O: -1.34%
H: 0.07%
C: -5.6%
treatment phase 2 china therapy cancer trial enroll
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.